Premium
Circulating antibodies to p40 AIS in the sera of respiratory tract cancer patients
Author(s) -
Yamaguchi K.,
Patturajan M.,
Trink B.,
Usadel H.,
Koch W.,
Jen J.,
Sidransky D.
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20001120)89:6<524::aid-ijc10>3.0.co;2-o
Subject(s) - antigen , antibody , lung cancer , lymph node , cancer , immunohistochemistry , immune system , western blot , transactivation , biology , grading (engineering) , immunology , pathology , cancer research , medicine , gene , gene expression , ecology , biochemistry
Studies of immune recognition in cancer have defined several tumor antigens using autologous cytotoxic T lymphocytes and by detection of serum antibodies to tumor‐associated products such as p53 and HER‐2/neu. The AIS gene is a p53 homologue with multiple protein products (p40, p51, p63, p73L) on chromosomal arm 3q, frequently amplified and over‐expressed in squamous‐cell carcinoma of the respiratory tract. We analyzed the humoral response to p40 AIS (a core domain of AIS products without the transactivation domain) by Western blot and ELISA using bacterially synthesized p40 AIS protein. Antibodies were detected in the sera of 17/94 (18%) HNSCCs and 13/76 (17%) lung cancers, including 5/18 (26%) squamous‐cell carcinomas. Anti‐p40 AIS antibodies were not associated with factors such as sex, age, histopathological grading, extent or size of primary tumor, lymph node involvement and staging. Our results indicate that amplification and over‐expression of p40 AIS may lead to antigen recognition by an autologous host with cancer. AIS may thus represent a new group of developmentally regulated genes that are recognized as tumor antigens. Int. J. Cancer 89:524–528, 2000. © 2000 Wiley‐Liss, Inc.